Invitae (NYSE:NVTA) Trading Down 5.1%
Invitae (NYSE:NVTA) Trading Down 5.1%
Invitae Co. (NYSE:NVTA – Get Rating)'s stock price fell 5.1% during mid-day trading on Friday . The company traded as low as $2.78 and last traded at $2.82. 37,359 shares were traded during mid-day trading, a decline of 100% from the average session volume of 9,110,689 shares. The stock had previously closed at $2.97.
Invitae Co.(纽约证券交易所代码：NVTA-GET Rating)股价周五午盘下跌5.1%。该公司股价最低跌至2.78美元，最新报2.82美元。午盘成交量为37,359股，较9,110,689股的平均成交量下降100%。该股此前收盘价为2.97美元。
Analysts Set New Price Targets
分析师设定新的价格目标
A number of equities analysts have weighed in on NVTA shares. William Blair reissued a "market perform" rating on shares of Invitae in a research note on Tuesday, November 8th. Cowen lifted their target price on Invitae to $2.80 in a research report on Tuesday, November 15th. Credit Suisse Group initiated coverage on Invitae in a research report on Wednesday, August 24th. They issued an "underperform" rating on the stock. JPMorgan Chase & Co. downgraded Invitae from a "neutral" rating to an "underweight" rating in a research report on Wednesday, August 10th. Finally, SVB Leerink lifted their target price on Invitae from $2.50 to $3.00 and gave the company a "market perform" rating in a research report on Wednesday, November 9th. Four equities research analysts have rated the stock with a sell rating and nine have issued a hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $8.04.
许多股票分析师对NVTA的股票进行了加码。11月8日，威廉·布莱尔在一份研究报告中重新发布了对Invitae股票的“市场表现”评级。考恩在11月15日周二的一份研究报告中将Invitae的目标价上调至2.80美元。瑞士信贷集团在8月24日星期三的一份研究报告中启动了对Invitae的报道。他们对该股给予了“表现不佳”的评级。摩根大通在8月10日周三的一份研究报告中将Invitae的评级从中性下调至减持。最后，SVB Leerink在11月9日(周三)的一份研究报告中将Invitae的目标价从2.50美元上调至3.00美元，并给予该公司“市场表现”评级。4名股票研究分析师对该股的评级为卖出，9名分析师对该公司的评级为持有。根据MarketBeat的数据，该公司的共识评级为持有，共识目标价为8.04美元。
Invitae Price Performance
Invitae性价比
The stock has a market capitalization of $689.84 million, a price-to-earnings ratio of -0.21 and a beta of 1.61. The company has a debt-to-equity ratio of 10.03, a quick ratio of 6.18 and a current ratio of 6.44. The company has a 50 day moving average of $2.58 and a 200 day moving average of $2.87.
该股市值为6.894亿美元，市盈率为-0.21倍，贝塔系数为1.61。该公司的负债权益比率为10.03，速动比率为6.18，流动比率为6.44。该公司的50日移动均线切入位在2.58美元，200日移动均线切入位在2.87美元。
Institutional Trading of Invitae
Invitae的制度性交易
A number of large investors have recently made changes to their positions in the company. ARK Investment Management LLC boosted its position in shares of Invitae by 6.3% in the 3rd quarter. ARK Investment Management LLC now owns 30,468,381 shares of the medical research company's stock valued at $74,952,000 after purchasing an additional 1,799,431 shares during the period. Vanguard Group Inc. raised its stake in Invitae by 2.6% during the 3rd quarter. Vanguard Group Inc. now owns 21,624,354 shares of the medical research company's stock valued at $53,196,000 after acquiring an additional 544,941 shares during the last quarter. Rock Springs Capital Management LP raised its stake in Invitae by 18.7% during the 1st quarter. Rock Springs Capital Management LP now owns 3,323,821 shares of the medical research company's stock valued at $26,491,000 after acquiring an additional 523,578 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Invitae by 34.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 2,551,464 shares of the medical research company's stock valued at $6,226,000 after acquiring an additional 647,362 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Invitae by 11.8% during the 2nd quarter. Northern Trust Corp now owns 2,132,881 shares of the medical research company's stock valued at $5,204,000 after acquiring an additional 225,589 shares during the last quarter. 88.27% of the stock is owned by institutional investors and hedge funds.
一些大型投资者最近对他们在该公司的头寸进行了调整。方舟投资管理有限责任公司在第三季度将其在Invitae股票的头寸增加了6.3%。方舟投资管理公司现在拥有30,468,381股这家医疗研究公司的股票，价值74,952,000美元，在此期间又购买了1,799,431股。先锋集团(Vanguard Group Inc.)第三季度增持Invitae股份2.6%。先锋集团(Vanguard Group Inc.)在上个季度增持了544,941股后，目前持有这家医疗研究公司21,624,354股票，价值53,196,000美元。Rock Springs Capital Management LP在第一季度将其在Invitae的持股增加了18.7%。Rock Springs Capital Management LP在上个季度增持了523,578股票后，现在拥有这家医疗研究公司3,323,821股票，价值26,491,000美元。高盛股份有限公司在第二季度增持了Invitae 34.0%的股份。高盛股份有限公司在上个季度增持了647,362股后，目前持有这家医学研究公司2,551,464股股票，价值6,226,000美元。最后，北方信托公司在第二季度将其在Invitae的持股比例提高了11.8%。Northern Trust Corp目前持有这家医疗研究公司2,132,881股股票，价值5,204,000美元，此前该公司在上个季度又收购了225,589股。88.27%的股票由机构投资者和对冲基金持有。
Invitae Company Profile
Invitae公司简介
(Get Rating)
(获取评级)
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services.
Invitae公司是一家医学遗传学公司，将遗传信息整合到主流医学中，以改善美国、加拿大和国际上人们的医疗保健。该公司提供各种临床领域的基因测试，包括遗传癌、心脏病学、神经病学、儿科、肿瘤学、代谢疾病和罕见疾病；数字健康解决方案；以及健康数据服务。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Invitae (NVTA)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
- 免费获取StockNews.com关于Invitae的研究报告(NVTA)
- 为什么CSL有限公司的股票值得一看
- MarketBeat：回顾一周11/28-12/02
- Okta Inc.庆祝收益节节攀升，但他们能持续这种提振吗？
- 机构正在购买安巴雷拉，你应该吗？
- ZIM能否抵御集装箱航运业的普遍低迷？
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.
接受《邀请日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Invitae和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。